The Physiological Role of FAS and IL-17A as a Markers in the Diagnosis of Rheumatoid Arthritis

Article Sidebar

PDF
Published: Jul 3, 2023
DOI: https://doi.org/10.47191/ijpbms/v3-i7-01
Keywords:
Rheumatoid arthritis; Fatty acid synthase; IL-17A; lipid profile; RF

Main Article Content

Hussein Saeed Al-Mafragy
Collage of Education for Pure Sciences, Karbala University, Iraq
Elham F. Hamzah
Department of medical physics, Al-Mustaqbal University College, Babylon, Iraq
Ahmed Neema AL-Mussawy
Department of Pathological Analysis, Collage of Science, Al-Qasim Green University, Iraq
Hamzah H. Kzar
Veterinary Medicine Collage, Al-Qasim Green University, Babylon, Iraq

Abstract

Objective: The chronic autoimmune disease affecting the joints that are characterized by a progressive symmetric inflammation of affected joints resulting in cartilage destruction, bone erosion, and disability has been called  Rheumatoid arthritis (RA). The aim of this study is to the assessment of FAS and lipid profiles in Iraqi patients with RA. Methods: In the current study, the demographic characteristics of the 90 studied subjects, 45 patients with RA, and 45 control subjects.


Results: The result showed statically significance for increased cholesterol, and LDL in the study group (p-value<0.0001,<0.001 respectively ), while HDL was found to be significant decrease (p-value< 0.001) and non-significant for TG, VLDL (p-value 0.1,0.09 respectively). The current study concludes that there is a significant difference in the level of the fatty acid synthase FAS enzyme between the patients (0.93 ± 0.53) and control group (0.74 ± 0.45), p-value (0.001) where the patients group has a higher level of the fatty acid synthase than the control group. This study conducted that there is a significant difference in the level of the IL-17A levels (pg/ml) between the patients (166 ± 13) and control group (87 ± 5), p-value (0.001) where the patients group has a higher level of the IL-17A  than the control group.


Conclusion: Assessment of both FAS and IL-17A may be given as an appropriate and useful method for diagnosis and following with patients with RA.

Article Details

How to Cite
Hussein Saeed Al-Mafragy, Elham F. Hamzah, Ahmed Neema AL-Mussawy, & Hamzah H. Kzar. (2023). The Physiological Role of FAS and IL-17A as a Markers in the Diagnosis of Rheumatoid Arthritis. International Journal of Pharmaceutical and Bio Medical Science, 3(07), 314–319. https://doi.org/10.47191/ijpbms/v3-i7-01
Issue
Vol. 3 No. 07 (2023): Volume 03 Issue 07 July 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet Lond. Engl. 2016;388:2023–2038.

II. Littlejohn E.A., Monrad S. Early Diagnosis and Treatment of Rheumatoid Arthritis. Prim. Care: Clin. Off. Pr. 2018;45:237–255.

III. Sacks J.J., Luo Y.-H., Helmick C.G. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005. Arthritis Rheum. 2010;62:460–464.

IV. Sangha O. Epidemiology of rheumatic diseases. Rheumatology. 2000;39:3–12.

doi: 10.1093/rheumatology/39.suppl_2.3.

V. Myasoedova E., Crowson C.S., Kremers H.M., Therneau T.M., Gabriel S.E. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–1582.

VI. Brzustewicz E., Henc I., Daca A., Szarecka M., Sochocka-Bykowska M., Witkowski J., Bryl E. Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment. Cent. Eur. J. Immunol. 2017;42:259–268.

VII. Aletaha D., Ramiro S. Diagnosis and Management of Rheumatoid Arthritis. JAMA. 2018;320:1360–1372.

VIII. Deane K.D., Demoruelle M.K., Kelmenson L.B., Kuhn K.A., Norris J.M., Holers V.M. Genetic and environmental risk factors for rheumatoid arthritis. Best Pr. Res. Clin. Rheumatol. 2017;31:3–18.

IX. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol. 2010;72:495–516.

X. Balasa R, Bajko Z, Hutanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Mult Scler. 2013;19:885–890.

XI. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med. 2003;97:726–733.

XII. Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136:531–545.

XIII. Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016;22:230–241.

XIV. Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase. Science. 2008;321:1315–22.

XV. Arrese EL, Soulages JL. Insect fat body: energy, metabolism, and regulation. Annu Rev Entomol. 2010;55:207–25.

XVI. Birch JT Jr, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim Care. 2010;37:779–92.

XVII. Scott DL. Early rheumatoid arthritis. British Medical Bulletin. 2007;81-82:97–114.

XVIII. Lindqvist H.M., Gjertsson I., Eneljung T., Winkvist A. Influence of blue mussel (Mytilusedulis) intake on disease activity in female patients with rheumatoid arthritis: The MIRA randomized cross-over dietary intervention. Nutrients. 2018;10:481.

XIX. Tański W, Świątoniowska-Lonc N, Tabin M, Jankowska-Polańska B. The Relationship between Fatty Acids and the Development, Course and Treatment of Rheumatoid Arthritis. Nutrients. 2022 Feb 28;14(5):1030.

XX. Bahadori B., Uitz E., Thonhofer R., Trummer M., Pestemer-Lach I., McCarty M., Krejs G.J. Omega-3 Fatty acids infusions as adjuvant therapy in rheumatoid arthritis. JPEN J. Parenter. Enteral. Nutr. 2010;34:151–155.

XXI. Kolahi S., Ghorbanihaghjo A., Alizadeh S., Rashtchizadeh N., Argani H., Khabazzi A.R., Hajialilo M., Bahreini E. Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin. Biochem. 2010;43:576–580.

XXII. Dawczynski C., Schubert R., Hein G., Müller A., Eidner T., Vogelsang H., Basu S., Jahreis G. Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: Effects on pathophysiological biomarkers in patients with rheumatoid arthritis. Br. J. Nutr. 2009;101:1517–1526.

XXIII. Hamzah H. Kzar, Moshtak A. wtwt, Moaed E. Al-Gazally. Study the Glucose Transport, Angiogenesis and Apoptosis Behavioral through Chemotherapy Treatment According to Receptors Status in Women with Breast Cancer. IJFMT, 2020;14(3), 2555-2559.

XXIV. Ali SH, AL-Azawi RSA, Kzar HH. Study the IL6 (C174G) Promoter SNP and Correlation with Physiological Growth Hormone and TNFA levels in Iraqi Subjects with Psoriasis. SRP. 2020; 11(9): 272-276.

XXV. Galarraga B., Ho M., Youssef H.M., Hill A., McMahon H., Hall C., Ogston S., Nuki G., Belch J.J. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology. 2008;47:665–669.

XXVI. Fraser D.A., Thoen J., Rustan A.C., Førre O., Kjeldsen-Kragh J. Changes in plasma free fatty acid concentrations in rheumatoid arthritis patients during fasting and their effects upon T-lymphocyte proliferation. Rheumatology. 1999;38:948–952.

XXVII. Robert M, Miossec P. IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. Front Med (Lausanne). 2019 Jan 14;5:364.